Mar 2026 $1 M Private placement after listing Under $2 million 1
Pulmatrix, Inc.: Private sale, Mar 2026 × Investors in this round 1 investor had bought by the notice of Apr 15, 2026: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $1,000,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Peter Ludlum · Executive Officer · Interim CEO; Interim CFO Anand Varadan · Director Christopher Cabell · Director Michael Higgins · Director Richard Batycky · Director Todd Bazemore · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The issuer issued 1,000 shares of Series B Convertible Preferred Stock, stated value $1,000 per share for aggregate proceeds of $1,000,000 in a private placement pursuant to Rule 506(b) of Regulation D.”On a merger: “In connection with the signing of the Merger Agreement with Eos SENOLYTIX, Inc.”Signed by Peter Ludlum, Interim CEO, Interim CFO. Source: SEC Form D, newest notice filed Apr 15, 2026. Read the notice at the SEC .
equity SEC Apr 2020 $8 M Private placement after listing $2 to $10 million 3
Pulmatrix, Inc.: Private sale, Apr 2020 × Investors in this round 3 investors had bought by the notice of Apr 24, 2020: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $560,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Michelle S. Siegert · Executive Officer, Director · Vice President of Finance Teofilo Raad · Executive Officer, Director · Chief Executive Officer and Director Amit D. Munshi · Director Mark J. Iwicki · Director Michael J. Higgins · Director · Chairman of Board of Directors Richard D. Batycky · Director Steven Gillis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states Remarks in the notice On fees: “H.C. Wainwright & Co., LLC received the above sales commission and the warrants in connection with the private placement and a concurrent registered direct offering by the Issuer, which is not reported on this Form D.”On the amounts: “Represents warrants to investors to purchase up to 4,787,553 common shares at $1.55/share and warrants to H.C. Wainwright & Co., LLC to purchase up to 311,191 common shares at $2.0888/share, in connection with a 4/16/20 registered direct offering.”Signed by Teofilo Raad, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Apr 24, 2020. Read the notice at the SEC .
options SEC Feb 2019 $2 M Private placement after listing $2 to $10 million 7
Pulmatrix, Inc.: Private sale, Feb 2019 × Investors in this round 7 investors had bought by the notice of Feb 14, 2019: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $200,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Roach · Executive Officer · Chief Medical Officer Robert Clarke · Executive Officer, Director · Chief Executive Officer, President and Director Teofilo Raad · Executive Officer · Chief Business Officer William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary Amit Munshi · Director Mark Iwicki · Director Matthew Sherman · Director Michael Higgins · Director Steven Gillis · Director Terrance McGuire · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states Remarks in the notice On fees: “H.C. Wainwright & Co., LLC received the above sales commission and the warrants in connection with the private placement and a concurrent registered direct offering by the Issuer, which is not reported on this Form D.”On the amounts: “Includes warrants to purchase up to 1,706,484 shares of common stock at an exercise price of $1.34/share, issued to certain investors, and up to 110,922 shares of common stock at an exercise price of $1.8313/share, issued to H.C. Wainwright & Co., LLC.”Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Feb 14, 2019. Read the notice at the SEC .
options SEC Dec 2018 $4 M Private placement after listing $2 to $10 million 1
Pulmatrix, Inc.: Private sale, Dec 2018 × Investors in this round 1 investor had bought by the notice of Dec 18, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Roach · Executive Officer · Chief Medical Officer Robert Clarke · Executive Officer, Director · Chief Executive Officer, President and Director Teofilo Raad · Executive Officer · Chief Business Officer William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary Amit Munshi · Director Mark Iwicki · Director Matthew Sherman · Director Michael Higgins · Director Steven Gillis · Director Terrance McGuire · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents the issuance of common warrants to purchase an aggregate of 9,375,000 shares of common stock at an exercise price of $0.39 per share.”Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Dec 18, 2018. Read the notice at the SEC .
options SEC Jun 2015 $21 M Private placement after listing $10 to $50 million 12
Pulmatrix, Inc.: Private sale, Jun 2015 × Investors in this round 12 investors had bought by the notice of Jun 30, 2015: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $21 M of $45 M offered; $24 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Hava · Executive Officer · Chief Scientific Officer Hojabr Alimi · Executive Officer, Promoter · Former Chief Executive Officer Robert Clarke · Executive Officer, Director · Chief Executive Officer and Member of the Board of Directors Sameer Harish · Executive Officer, Promoter · Former Chief Financial Officer William Duke · Executive Officer · Chief Financial Officer, Treasurer and Secretary David Maki · Director Gregory French · Director, Promoter · Former Member of the Board of Directors Kurt Graves · Director Michael Higgins · Director Richard Conley · Director, Promoter · Former Member of the Board of Directors Scott Rocklage · Director Steven Gillis · Director Terrance McGuire · Director Oculus Innovative Sciences, Inc. · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount includes (i) $21,383,416, representing shares that were issued in the merger and (ii) $24,084,696, representing the total aggregate exercise price of warrants issued in the merger.”On a merger: “The offering was made in connection with a merger between Pulmatrix Operating Company, Inc. and Pulmatrix, Inc. A portion of the offering was cross-conditioned with the closing of the merger.”Signed by William Duke, Jr., Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jun 30, 2015. Read the notice at the SEC .
equity, options SEC Jun 2015 $3 M Private placement after listing $2 to $10 million 34
Pulmatrix, Inc.: Private sale, Jun 2015 × Investors in this round 34 investors had bought by the notice of Jun 16, 2015: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $4,950
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $208,662
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Hojabr Alimi · Executive Officer Sameer Harish · Executive Officer Akihisa Akao · Director Gregory French · Director Richard Conley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Dawson James Securities Inc. (CRD 130645) · Boca Raton, Florida Sold in AK, CA, CT, FL, IN, MA, MD, MN, NJ, NV, NY Remarks in the notice On fees: “Does not include a 1% non-accountable expense allowance”On the amounts: “Offering is closed.”Signed by Hojabr Alimi, Ceo. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC .
equity SEC